Cytokinetics Inc.
CYTKCytokinetics Inc. (CYTK) is a biopharmaceutical company focused on developing muscle biology-based therapies for debilitating diseases. The company's key areas of interest include treatments for conditions such as amyotrophic lateral sclerosis (ALS), heart failure, and other muscle-related disorders. Cytokinetics leverages its expertise in muscle contractility and cytoskeletal proteins to discover, develop, and commercialize innovative therapeutic agents.
Company News
Cytokinetics granted stock options to purchase 29,416 shares and 19,825 restricted stock units to 8 employees hired in December 2025 and January 2026 as material inducements to employment. The stock options have an exercise price of $63.44 per share and vest over 4 years, while RSUs vest over 3 years with a 40-40-20 schedule.
Cytokinetics' CEO Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, a specialty cardiovascular biopharmaceutical firm, has FDA-approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy and is advancing a pipeline of cardiac muscle dysfu...
Tango Therapeutics announced the appointment of Sung Lee, Executive Vice President and CFO at Cytokinetics, to its Board of Directors. Lee brings over 20 years of finance leadership experience from roles at major biopharmaceutical companies including Vir Biotechnology, MorphoSys, Sangamo Therapeutics, and Gilead Sciences. His appointment is inten...
Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Cytokinetics faces allegations of misleading statements regarding FDA decisions on its aficamten drug application. Molina Healthcare is accused of failing to disclose adverse medical cost trends and guidance ...
Cytokinetics announced FDA approval of MYQORZO (aficamten), a cardiac myosin inhibitor for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on the SEQUOIA-HCM Phase 3 trial, which demonstrated significant improvements in exercise capacity and symptom relief. The drug will be available in the U.S. in the s...
